A Study Examining the Medication Apremilast as Treatment for Chronic Itch
Status:
Completed
Trial end date:
2019-09-19
Target enrollment:
Participant gender:
Summary
Chronic Itch is a debilitating condition affecting many people. Currently, there are no
FDA-approved treatments. Apremilast is an FDA-approved oral medication used to successfully
treat the inflammatory skin disorder psoriasis and the inflammatory disorder psoriatic
arthritis. This study examines if apremiliast taken twice daily relieves chronic itch.